Molecular profile
Molecular profile
- Molecule class
- Peptide analogue
- Origin
- Synthetic analogue
- Primary target system
- GIP-, GLP-1- und Glukagonrezeptoren
- Development stage
- Clinical development
Langwirksames, acyliertes Multi-Rezeptor-Peptidanalogon.
Mechanism and signalling
Mechanism and signalling
Its mechanism combines incretin signalling with glucagon-receptor effects on energy and substrate metabolism.
Scientific classification
Scientific classification
This profile maps Retatrutid to the research areas metabolism, endocrine. Molecule class, evidence level, development stage and regulatory status are separated so that preclinical findings are not confused with authorised uses.
Pathways related to glucose homeostasis, appetite, energy expenditure and body composition.
Peptide hormones and analogues related to hypothalamic, pituitary and peripheral endocrine systems.
Evidence base
Phase III
Phase II data and ongoing phase III trials form the current evidence base. Benefit–risk remains uncertain until programmes and regulatory review are complete.
Regulatory status
Investigational substance
The substance remains in clinical development and is not authorised as a generally available medicine. Trial status and regulatory assessment may change.
Safety and use notice
No dosing or administration recommendation
The available evidence does not establish safe self-directed use. This profile intentionally provides no dosing, sourcing or administration guidance.
Sources and registries